Hikma Pharmaceuticals PLC (LON:HIK) Given Average Rating of “Buy” by Analysts

Hikma Pharmaceuticals PLC (LON:HIK) has earned a consensus recommendation of “Buy” from the six brokerages that are presently covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month price target among brokers that have issued ratings on the stock in the last year is GBX 1,687.

A number of brokerages recently issued reports on HIK. Jefferies Financial Group increased their target price on Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Berenberg Bank restated a “buy” rating and set a GBX 1,800 price target on shares of Hikma Pharmaceuticals in a research note on Tuesday, April 28th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a GBX 195 price objective on shares of Hikma Pharmaceuticals in a report on Monday, June 22nd. Finally, Citigroup reaffirmed a “buy” rating on shares of Hikma Pharmaceuticals in a research note on Thursday.

Hikma Pharmaceuticals Trading Up 1.9%

Shares of Hikma Pharmaceuticals stock opened at GBX 1,523.60 on Thursday. The company has a debt-to-equity ratio of 61.84, a quick ratio of 1.27 and a current ratio of 1.82. Hikma Pharmaceuticals has a 52 week low of GBX 1,187 and a 52 week high of GBX 2,052. The stock has a 50 day moving average price of GBX 1,487.53 and a two-hundred day moving average price of GBX 1,448.63. The stock has a market capitalization of £3.21 billion, a PE ratio of 8.42, a price-to-earnings-growth ratio of 2.38 and a beta of 0.65.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.